In medicine, myopathy is a disease of the muscle in which the muscle fibers do not function properly. This results in muscular weakness. Myopathy means muscle disease (Greek : myo- muscle + patheia -pathy : suffering). This meaning implies that the primary defect is within the muscle, as opposed to the nerves ("neuropathies" or "neurogenic" disorders) or elsewhere (e.g., the brain). Muscle cramps, stiffness, and spasm can also be associated with myopathy.
Signs and symptoms
Myopathies in systemic disease results from several different disease processes including endocrine, inflammatory, paraneoplastic, infectious, drug- and toxin-induced, critical illness myopathy, metabolic, collagen related, and myopathies with other systemic disorders. Patients with systemic myopathies often present acutely or sub acutely. On the other hand, familial myopathies or dystrophies generally present in a chronic fashion with exceptions of metabolic myopathies where symptoms on occasion can be precipitated acutely. Most of the inflammatory myopathies can have a chance association with malignant lesion; the incidence appears to be specifically increased only in patients with dermatomyositis.
There are many types of myopathy. ICD-10 codes are provided here where available.
- (G71.0) Dystrophies (or muscular dystrophies) are a subgroup of myopathies characterized by muscle degeneration and regeneration. Clinically, muscular dystrophies are typically progressive, because the muscles' ability to regenerate is eventually lost, leading to progressive weakness, often leading to use of a wheelchair, and eventually death, usually related to respiratory weakness.
- (G71.1) Myotonia
- (G71.2) The congenital myopathies do not show evidence for either a progressive dystrophic process (i.e., muscle death) or inflammation, but instead characteristic microscopic changes are seen in association with reduced contractile ability of the muscles. Congenital myopathies include, but are not limited to:
- (G71.2) nemaline myopathy (characterized by presence of "nemaline rods" in the muscle),
- (G71.2) multi/minicore myopathy (characterized by multiple small "cores" or areas of disruption in the muscle fibers),
- (G71.2) centronuclear myopathy (or myotubular myopathy) (in which the nuclei are abnormally found in the center of the muscle fibers), a rare muscle wasting disorder
- (G71.3) Mitochondrial myopathies, which are due to defects in mitochondria, which provide a critical source of energy for muscle
- (G72.3) Familial periodic paralysis
- (G72.4) Inflammatory myopathies, which are caused by problems with the immune system attacking components of the muscle, leading to signs of inflammation in the muscle
- (G73.6) Metabolic myopathies, which result from defects in biochemical metabolism that primarily affect muscle
- (G72.89) Other myopathies
- (G72.0 - G72.2) External substance induced myopathy
- (G72.0) Drug-induced myopathy
- (G72.1) Alcoholic myopathy
- (G72.2) Myopathy due to other toxic agents - including atypical myopathy in horses caused by toxins in sycamore seeds and seedlings.
- Dermatomyositis produces muscle weakness and skin changes. The skin rash is reddish and most commonly occurs on the face, especially around the eyes, and over the knuckles and elbows. Ragged nail folds with visible capillaries can be present. It can often be treated by drugs like corticosteroids or immunosuppressants. (M33.2)
- Polymyositis produces muscle weakness. It can often be treated by drugs like corticosteroids or immunosuppressants.
- Inclusion body myositis is a slowly progressive disease that produces weakness of hand grip and straightening of the knees. No effective treatment is known.
- (M61) Myositis ossificans
- (M62.89) Rhabdomyolysis and (R82.1) myoglobinurias
The Food and Drug Administration is recommending that physicians restrict prescribing high-dose Simvastatin (Zocor, Merck) to patients, given an increased risk of muscle damage. The FDA drug safety communication stated that physicians should limit using the 80-mg dose unless the patient has already been taking the drug for 12 months and there is no evidence of myopathy. "Simvastatin 80 mg should not be started in new patients, including patients already taking lower doses of the drug," the agency states.
- (I40) Acute myocarditis
- (I41) Myocarditis in diseases classified elsewhere
- (I42) Cardiomyopathy
- (I42.0) Dilated cardiomyopathy
- (I42.1) Obstructive hypertrophy cardiomyopathy
- (I42.2) Other hypertrophic cardiomyopathy
- (I42.3) Endomyocardial (eosinophilic) disease
- (I42.4) Endocardial fibroelastosis
- (I42.5) Other restrictive cardiomyopathy
- (I42.6) Alcoholic cardiomyopathy
- (I42.8) Other cardiomyopathies
- (I43) Cardiomyopathy in diseases classified elsewhere
- None as systemic causes; mainly hereditary
Onset in childhood
- Inflammatory myopathies – dermatomyositis, polymyositis (rarely)
- Infectious myopathies
- Endocrine and metabolic disorders – hypokalemia, hypocalcemia, hypercalcemia
Onset in adulthood
- Inflammatory myopathies – polymyositis, dermatomyositis, inclusion body myositis, viral (HIV)
- Infectious myopathies
- Endocrine myopathies – thyroid, parathyroid, adrenal, pituitary disorders
- Toxic myopathies – alcohol, corticosteroids, narcotics, colchicines, chloroquine
- Critical illness myopathy
- Metabolic myopathies
- Paraneoplastic myopathy
Because different types of myopathies are caused by many different pathways, there is no single treatment for myopathy. Treatments range from treatment of the symptoms to very specific cause-targeting treatments. Drug therapy, physical therapy, bracing for support, surgery, and massage are all current treatments for a variety of myopathies.
- "Myopathy - Definition from the Merriam-Webster Online Dictionary".
- Voermans NC, van Alfen N, Pillen S, Lammens M, Schalkwijk J, Zwarts MJ, van Rooij IA, Hamel BC, van Engelen BG (June 2009). "Neuromuscular involvement in various types of Ehlers-Danlos syndrome". Ann. Neurol. 65 (6): 687–97. doi:10.1002/ana.21643. PMID 19557868. S2CID 22600065.
- Chawla J (2011). "Stepwise approach to myopathy in systemic disease". Front Neurol. 2: 49. doi:10.3389/fneur.2011.00049. PMC 3153853. PMID 21886637.
- Seene T (July 1994). "Turnover of skeletal muscle contractile proteins in glucocorticoid myopathy". J. Steroid Biochem. Mol. Biol. 50 (1–2): 1–4. doi:10.1016/0960-0760(94)90165-1. PMID 8049126. S2CID 27814895.
- "Information On Sycamore Poisoning". Rainbow Equine Hospital. Retrieved 16 May 2017.
- "Equine Atypical Myopathy toxin and biochemical tests and tree sample testing available at the RVC". Royal Veterinary college - University of London. 13 February 2017. Retrieved 16 May 2017.
- "2019 ICD-10-CM Diagnosis Code I42.9: Cardiomyopathy, unspecified". The Web's Free 2019 ICD-10-CM/PCS Medical Coding Reference. 2018-10-01. Retrieved 2019-02-05.
- GeneReviews/NCBI/NIH/UW entry on Myopathy with Deficiency of ISCU
- See http://neuromuscular.wustl.edu/ for medical descriptions.